# Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision.

> **NCT00392314** · PHASE2 · COMPLETED · sponsor: **Rambam Health Care Campus** · enrollment: 365 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **OTHER:** PET/CT post 2 cycles of chemotherapy

## Key facts

- **NCT ID:** NCT00392314
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2014-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392314, "Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision.". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00392314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*